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Abstract
Background/Aims—Patients with chronic kidney disease (CKD) have high prevalence of
periodontal disease that may predispose to tooth loss and inflammation. The goal of this study was
to test the hypotheses that a genetic rat model of progressive CKD would exhibit altered oral bone
properties and that treatment with either bisphosphonates or calcium could attenuate these adverse
changes.
Methods—At 25 weeks of age, rats were treated with zoledronate, calcium gluconate, or their
combination for 5 or 10 weeks. Mandible bone properties were assessed using micro-computed
tomography to determine bone volume (BV/TV) and cement-enamel junction to alveolar crest
distance (CEJ-AC).
Results—Untreated CKD animals had significantly lower BV/TV at both 30 (−5%) and 35
(−14%) weeks of age and higher CEJ-AC (+27 and 29%) compared to normal animals. CKD
animals had significantly higher PTH compared to normal animals yet similar levels of C-reactive
protein. Zoledronate-treatment normalized BV/TV over the first 5 weeks but this benefit was lost
by 10 weeks. Calcium treatment, alone or in combination with zoledronate, was effective in
normalizing BV/TV at both time points. Neither zoledronate nor calcium was able to correct the
higher CEJ-AC caused by CKD. Calcium, but not zoledronate, significantly reduced serum
parathyroid hormone (PTH) while neither treatment affected C-reactive protein.
Conclusions—1) this progressive animal model of chronic kidney disease shows a clear
mandibular skeletal phenotype consistent with periodontitis, 2) the periodontitis is not associated
with systemic inflammation as measured by C-reactive protein, and 3) reducing PTH has positive
effects on the mandible phenotype.
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INTRODUCTION
Chronic kidney disease (CKD) is often accompanied by disturbances in mineral metabolism
which are classified as their own clinical entity known as CKD-mineral and bone disorder
(CKD-MBD) (1). CKD-MBD is hallmarked by altered bone remodeling and loss of bone
mass throughout the skeleton, including the oral cavity (2,3). Periodontal disease, including
gingivitis and periodontitis are more prevalent in CKD populations compared to healthy
individuals (4-6) and have been documented in rodent models of CKD (7). Peridontitis is
associated with alveolar bone loss, thought to be secondary to local inflammation and
change in the bacterial environment. Secondary hyperparathyroidism is common in CKD,
and oral bone remodeling is similar to that of cortical bone remodeling. Therefore, the
etiology of periodontitis in CKD may be due to inflammation and/or secondary
hyperparathyroidism (8). If the latter is true, then therapies that lower PTH may also have a
beneficial effect, as may other bone-sparing treatments that reduce remodeling such as
bisphosphonates.
Bisphosphonates have clear efficacy in reducing bone loss in non-CKD patients (9).
International clinical practice guidelines recommend bisphosphonates use in patients with
CKD stages 1-3 and normal parathyroid hormone levels, but recommended not using
bisphosphonates in patients with CKD stages 3-5 with biochemical evidence
hyperparathyroidism (1). The main concern for this latter population is the potential of
severely suppressed bone turnover although the limited clinical data does not universally
support such an effect (10-13). Recently, using an animal model of progressive kidney
disease we have documented that the reduction in remodeling of the tibia with zoledronic
acid is similar that that of normal animals (14) although this dose failed to normalize
biomechanical properties.
The effects of bisphosphonates on the oral skeleton have been extensively reviewed and
discussed in recent years do to the condition of osteonecrosis of the jaw (15,16). Although
cases of ONJ have been documented in persons treated with oral bisphosphonates, the vast
majority of cases have occurred in association with high dose intravenous bisphosphonates.
Indeed, oral bisphosphonates have actually been shown to benefit the oral skeleton. Oral
alendronate and risedronate have each showed efficacy in attenuating periodontal-induced
bone loss in the general population (17,18).
The goal of this study was to characterize the oral cavity skeletal changes in this progressive
kidney disease animal model. Specifically, we aimed to test the hypothesis that skeletal
properties in the oral cavity would be adversely affected in animals with CKD and that
bisphosphonates would attenuate these effects. We also aimed to understand the respective
roles of hyperparathyroidism versus inflammation in these periodontal changes.
METHODS
Animal model and experimental design
A rat colony with an autosomal dominant polycystic kidney disease, maintained at the
Indiana University School of Medicine, were used for this study. Male heterozygous rats
(Cy/+) develop characteristics of CKD (azotemia, anemia, hypertension, secondary
hyperparathyroidism) around 10 weeks of age. BUN analyses were conducted in all animals
at 10 weeks of age and animals with values over 40 mg/dl were considered to have CKD.
These animals have a progressive rise in PTH as they age, (19-21), and all animals had
elevations in PTH at the time of treatment.. The normal littermates of the colony were used
as non-affected (normal) controls.
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At 25 weeks of age (roughly a glomerular filtration rate of 25 ml/min, equivalent to human
stage 4 CKD), animals were assigned to treatment groups within two different experiments
that differed somewhat in drug dosages and also treatment duration (Figure 1).
Experiment one—CKD animals were treated with a single dose of vehicle, ZOL (one
group at 20 and another group at 100 μg/kg BW) or given 3% calcium gluconate in the
drinking water. Normal animals injected with either vehicle (saline) or a single
intraperotenal injection of zoledronic acid (ZOL, 100 μg/kg body weight) served as controls.
These single doses of ZOL have been shown to significantly suppress remodeling in the
tibia in this model over the five week timeframe, and this dose of calcium significantly
lowers PTH (14). Animals were sacrificed at 30 weeks of age (5 weeks after treatment
initiation).
Experiment two—CKD animals were treated with a single dose of vehicle, ZOL (20 μg/
kg BW), calcium gluconate, or calcium gluconate plus ZOL. Normal animals injected with
either vehicle (saline) or a single intraperotenal injection of zoledronic acid (ZOL, 20 μg/kg
body weight) served as controls. Animals were sacrificed at 35 weeks of age (10 weeks after
treatment initiation)
In both studies, all animals were euthanized by an overdose of sodium pentobarbital. At
necropsy, blood was collected by cardiac puncture. The right hemi-mandible was wrapped
in saline-soaked gauze and frozen for imaging. All procedures were reviewed and approved
by the Indiana University School of Medicine Institutional Animal Care and Use
Committee.
Computed tomography
Morphological parameters of the mandible were assessed using high-resolution micro-CT
(Skyscan 1172). Bones were wrapped in parafilm to prevent drying during the scanning.
Scans were obtained using an x-ray source, set at 60kV with a 12-μm pixel size. Images
were reconstructed and analyzed using standard Skyscan software (NRecon and CTAn,
respectively). A single slice from the central region of the first mandible molar was analyzed
for total bone volume (excluding the molar and incisor) and lingual cementum-enamel to
alveolar bone crest distance (CEJ-AC) as previously described (22,23). This distance is
roughly equivalent to the clinically assessed periodontal pocket, which is believed the nidus
of inflammation (Figure 2).
Biochemical analyses
Serum intact PTH, c-reactive protein, and TNFalpha were measured by ELISA (Alpco,
Salem NH) according to the manufacturer’s instruction. Calcium and phosphorous were
measured from plasma using colorimetric methods (14).
Statistics
All analyses were run using SAS software. All data were compared using a one-way
ANOVA with Fisher’s LSD post-hoc tests when appropriate. A p value of < 0.05 was used
to determine statistical significance. Data are presented as mean and standard error.
RESULTS
Detailed long bone tissue mass and biochemical data from experiment one (14) and two (24)
have been previously published. In both experiments one and two, there was no significant
difference among groups for body mass within either experiment while all CKD animals had
significantly larger kidney masses and elevated BUN indicative of progressive kidney
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disease. There were no significant differences in serum calcium or phosphorous at sacrifice
in experiment 1 (30 weeks) (14). However, in experiment two (treated for 10 weeks),
phosphorus was lower and calcium was higher in the calcium treated CKD animals
sacrificed at 35 weeks compared to other groups. At both time points PTH was significantly
higher in CKD animals (3x higher at 30 wks; 13x higher at 35 wks) while c-reactive protein
was not different at either time point (Tables 1 and 2). TNFalpha levels were undetectable in
all animals. In both experiments, the calcium treated animals had significant suppression of
PTH compared to control treated CKD animals and Normal animals. Thus, the animals had
progressive kidney disease and secondary hyperparathyroidism. Similar to human disease,
the animals developed progressive secondary hyperparathyroidism with frank
hyperphosphatemia late in the disease course. Treatment with calcium suppressed PTH and
lowered phosphorus, but also increased calcium levels when the treatment was given for 10
weeks.
Across both experiments, CKD-vehicle animals displayed a clear and consistent mandibular
phenotype compared to normal-vehicle animals (Figures 3). Mandible bone volume/tissue
volume was 6% lower and cementum-enamel junction to alveolar crest (CDJ-AC) distance
27% larger in the CKD animals compared to normal animals at 30 weeks of age. At 35
weeks of age, BV/TV was 14% lower and CDJ-AC 30% higher in CKD animals compared
to normal. Zoledronic acid did not significantly alter either periodontal assessment in normal
animals of either experiment (Figure 3). Zoledronic acid treatment in experiment 1 (5 weeks
of treatment) significantly improved trabecular BV/TV, at both doses with no dose response,
relative to CKD-VEH. Conversely, there was no effect of ZOL on BV/TV relative to CKD-
VEH in experiment two (10 weeks of treatment and more severe disease). ZOL was
ineffective in normalizing CEJ-AC distance in both experiments PTH levels (Table 1) were
significantly lower with the high dose, but not low dose, ZOL in experiment 1 relative to
CKD-VEH animals yet was still 2x higher than normal. Low dose ZOL in experiment 2
significantly reduced PTH relative to CKD-VEH yet it remained nearly 10-fold higher than
normal. c-reactive protein was significantly lower in ZOL-treated animals of experiment two
relative to CKD-VEH for unclear reasons.
Calcium supplementation normalized BV/TV in both experiments (Figure 3). Combining
calcium with zoledronic acid in experiment two produced BV/TV values comparable to
calcium alone. In experiment one, CEJ-AC was not different from normal but was also not
different from CKD-VEH. In experiment two, neither calcium alone nor calcium combined
with zoledronic acid affected CDJ-AC relative to CKD-VEH. Calcium, either alone or in
combination with ZOL significantly lowered serum PTH to below normal vehicle levels.
Calcium alone, in experiment two, resulted in c-reactive protein levels that were
significantly higher than normal (Table 1). In the CKD animals, the PTH level was inversely
correlated with the BV/TV (r = −0.77, p < 0.001), although not significantly correlated with
the CEJ-AC.
DISCUSSION
Previous work describing the skeletal properties in this progressive, genetically-based CKD
animal model has focused on the long bones and has documented increased bone remodeling
rates, loss of bone mass, and reduced biomechanical properties (14,21,25). Due to the
increasingly prevalent recognition of dental co-morbidities associated with CKD (5,6) and
recent documentation of mandibular phenotype in a mouse model of CKD (7), we examined
properties of the mandible that are known to be factors in the etiology of periodontal disease
in our model. Our results demonstrate that this animal model that develops progressive
CKD, has a mandible phenotype consistent with clinical periodontal disease. Specifically,
vehicle-treated CKD animals had a modest, but significantly lower mandible bone volume in
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the region of the first mandible molar compared to normal vehicle animals. CKD animals
also had significantly greater cementum-enamel junction to alveolar crest distance compared
to normal animals, indicative of alveolar crest bone resorption. These skeletal differences
existed in the context of significantly higher serum PTH but no difference in serum c-
reactive protein, compared to normal animals. The morphological changes observed in this
CKD animal model is consistent with those shown previously for both experimentally-
(ligature placement) and pharmacologically-induced periodontal disease (26,27) as well as
those for another animal model of CKD (7). Alterations in facial bones, including the
mandible, have also previously been documented in a small cohort of dialysis patients where
PTH is elevated (28).
Bisphosphonates as a therapy for oral bone loss have been explored, and shown to be
clinically effective in non-CKD populations(17,18). In our study, zoledronate treatment, at
both low and high doses, corrected difference in mandible bone volume in the short-term (5
week experiment) but not the long term (10 week experiment). Enhanced bone volume was
expected given that the mechanism of action for bisphosphonates is to reduce bone
remodeling. These positive effects are consistent with the effects of zoledronate at other
skeletal sites in these same animals (14), as well as a wide-array of other animal model
conditions of bisphosphonate treatment (29). The inability of zoledronic acid to normalize
bone volume in the 10 week study was unexpected. Previous work has shown a single 20
μg/kg dose of zoledronic acid maintained beneficial effects on tibia BV/TV bone up to eight
months post-dose in rats (30). We interpret this as evidence that CKD alters the long-term
efficacy of a single zoledronic acid dose, likely related to the high PTH that leads to
resorption of bone that is covered with the zoledronic acid, leading to less efficacy of the
drug. This could be potentially overcome by more frequent dosing – although a theoretical
concern exists that with compromised renal function, increased dosing will lead to increased
accumulation of drug in the skeleton and the potential adverse effects this could manifest.
The clinical utility of bisphosphonates for treating/preventing oral bone loss has been
curtailed by osteonecrosis of the jaw, a rare but significant side effect of potent remodeling
suppressive drugs (31). The mechanism underlying osteonecrosis of the jaw remains unclear
and although dramatic suppression of remodeling appears to play a role there are also a
number of other co-factors that likely are involved (16). Pre-clinical data show that
bisphosphonates do not suppress remodeling differently in a high-turnover model of CKD
compared to unaffected normal animals (14). This would suggest that risk of osteonecrosis
of the jaw, if it’s related to level of turnover suppression, would not be expected to be higher
in patients with high-turnover kidney disease.
The adverse effects of CKD on the cementum-enamel junction to the alveolar crest distance
were not altered with zoledronate treatment. Trabecular and intracortical bone envelopes
undergo bone remodeling, the coupled process of resorption followed by formation, similar
to that in long bones. In these situations, inhibition of remodeling with bisphosphonates
results in a small but meaningful increase in bone mass because 1) those sites that were in
the process of remodeling fill in and 2) no new remodeling sites are initiated. The cellular
activity on the alveolar bone surfaces is mostly modeling, the process of resorption or
formation (but not both) at a given spatial location. High PTH induced by CKD potently
stimulates resorption and this is likely the mechanism underlying the greater CEJ-AC in
CKD animals compared to normal (7,28). Suppression of osteoclast-based modeling, as
occurs with zoledronic acid, would slow the increase of CEJ-AC distance, but would not be
expected to reverse it. Non CKD-models of periodontal disease have documented that when
bisphosphonate treatment is initiated before the induction of periodontal disease the CEJ-AC
distance can be maintained (22). We interpret the lack of effect in our study as evidence that
the increase in CEJ-AC occurred prior to the zoledronic acid dosing (25 weeks of age).
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Given that PTH levels were already elevated at this age, this is a plausible hypothesis.
Modifications of CEJ-AC, a clinically-relevant parameter, would therefor necessitate either
earlier treatment with an anti-resorptive or treatment with an anabolic therapy, such as
parathyroid hormone (32) or anti-sclerostin antibody (33).
Calcium supplementation, utilized clinically to lower phosphorus when taken with meals,
and reduce elevated PTH, provided a prolonged effect on mandible BV/TV maintenance. At
both 5 and 10 week time points, animals treated with calcium had BV/TV that was
comparable to normal animals, suggesting the control of PTH has a greater effect on bone
preservation than the potent but acute treatment with bisphosphonate. Yet similar to
zoledronic acid, calcium supplementation was not able to restore CEJ-AC distance, again
likely because changes to this parameter occurred prior to the initiation of treatment.
In vehicle-treated animals, serum PTH was significantly higher in CKD animals compared
to normal while there was no difference in c-reactive protein, an outcome measure related to
inflammation (34). Further supporting that systemic inflammation was not an etiology in the
changes were the undetectable levels TNF-alpha. In the calcium treated groups, serum PTH
and bone volume were maintained; in contrast PTH was not controlled, nor bone volume
maintained in animals treated with zoledronate. These observations confirm previous
observations that hyperparathyroidism was associated with mandibular bone changes in a
different animal model of CKD and in a small cohort of dialysis patients (7,28). We also
found a significant negative correlation between PTH and bone volume, similar to that
observed in the mouse model of CKD-MBD (7). Inflammation, globally assessed by CRP, is
also associated with periodontal disease. However, inflammation may be a result, rather than
a cause of periodontitis. This induced systemic inflammation may be a cause of CKD, rather
than CKD itself leading to periodontal disease (8,35). In the present study, the effects of
treatment on C-reactive protein were modest and did not track with response of bone. Based
on these outcomes and measurements, we conclude that PTH, not systemic inflammation,
drives the bone alterations observed in this CKD model. This highlights the need to control
PTH in order to reign in the oral skeletal manifestations of the disease in addition to the long
bone changes.
These results should be interpreted in the context of study limitations. Our study did not
include baseline controls, animals that are sacrificed at the time of treatment initiation. This
would have allowed us to determine if measures such as CEJ-AC were indeed different at
the start. We also did not have a group of animals that were dosed more frequently with
zoledronic acid (in experiment 2). This would have directly addressed whether controlling
PTH was essential to preserving bone volume or if simply controlling osteoclasts through
repeated dosing would also have been effective. We also did not have normal animals
treated with calcium or calcium plus zoledronic acid as the main reason to include the
normal animals was to define the basal phenotype of the rat model.
In conclusion we have documented that this model of progressive chronic kidney disease
presents a skeletal phenotype in the oral cavity consistent with clinically observed
periodontal disease and that zoledronate and calcium each have mixed effects as a treatment
for correcting this phenotype. We also provide evidence that the bone loss of periodontal
disease is related more to PTH levels than inflammation markers.
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Figure 1.
Experimental design. All animals began treatment at 25 weeks of age. Experiment 1 lasted
five weeks and experiment 2 lasted ten weeks. Animals were dosed with a single bolus of
saline vehicle (VEH) or zoledronic acid (ZOL). Animals in calcium groups were fed 3%
calcium gluconate in their water throughout the experimental duration.
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Figure 2.
CT-based morphological assessment of mandible bone. Bone volume per tissue volume
(BV/TV) was calculated as the fraction of tissue that was mineralized within the entire
section, excluding the dental tissue (area encompassed by the white dotted line). The
cementum-enamel junction to alveolar crest distance was calculated at the lingual surface as
noted by the arrow.
Allen et al. Page 10
Am J Nephrol. Author manuscript; available in PMC 2014 November 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3.
Effects of chronic kidney disease and its treatment with bisphosphonate, calcium, or their
combination on mandible trabecular bone volume (A, C) and cementum-enamel junction to
alveolar crest distance (B, D). Dotted line notes level of normal-vehicle animals for
reference across groups. VEH = vehicle, ZOL = zoledronate, Ca = calcium. Data as mean ±
SE. p < 0.05 versus normal vehicle (#), CKD-Vehicle (*), and (^) CKD-ZOL.
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TABLE 1
Serum biochemistry (30 weeks of age – 5 weeks of treatment)
Normal CKD 1way
ANOVA
Vehicle ZOL
100 μg
Vehicle ZOL
20 μg
ZOL
100 μg
Ca
Parathyroid
hormome,
pg/ml
(range)
251 ± 34
(104-382)
233 ± 16
(174-303) 853 ± 227 
#
(445-1870)
593 ± 95 #
(238-950)
558 ± 203 *
(217-4662)
162 ± 69 *^
(22-420)
0.0009
Serum c-
reactive
protein,
μg/ml
375 ± 15 376 ± 15 371 ± 8 353 ± 21 382 ± 20 350 ± 9 0.655
#
Data as mean ± SE. p < 0.05 versus normal vehicle
*CKD-Vehicle
^CKD-ZOL.
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TABLE 2
Serum biochemistry (35 weeks of age – 10 weeks of treatment)
Normal CKD 1way
ANOVA
Vehicle ZOL
20 μg
Vehicle ZOL
20 μg
Ca Ca + ZOL
Parathyroid
hormome,
pg/ml
(range)
230 ± 50 *
(108-613)
213 ± 17 *
(155-304)
3031 ± 332 #
(972-4760)
2119 ± 574 *#
(109-4769)
55 ± 14 *^
(20-4760)
69 ± 20 *^
(10-176)
<0.0001
Serum c-
reactive
protein,
μg/ml
459 ± 21 449 ± 17 519 ± 26 427 ± 16 * 528 ± 29 # 525 ± 29 0.0072
#
Data as mean ± SE. p < 0.05 versus normal vehicle
*CKD-Vehicle
^CKD-ZOL.
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